Compare STIM & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STIM | YARW |
|---|---|---|
| Founded | 2003 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.4M | 114.6M |
| IPO Year | 2018 | 2017 |
| Metric | STIM | YARW |
|---|---|---|
| Price | $2.18 | $18.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $5.75 | ★ $57.00 |
| AVG Volume (30 Days) | ★ 1.2M | 147.7K |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.25 | 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $52,776,000.00 | N/A |
| Revenue This Year | $8.63 | N/A |
| Revenue Next Year | $9.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $18.24 |
| 52 Week High | $3.44 | $44.28 |
| Indicator | STIM | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 28.16 | 26.28 |
| Support Level | $1.20 | N/A |
| Resistance Level | $2.32 | $32.89 |
| Average True Range (ATR) | 0.13 | 2.02 |
| MACD | -0.08 | -0.52 |
| Stochastic Oscillator | 1.75 | 2.68 |
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.